TAVR: The Need for a Pacemaker Is Associated with Mortality

Courtesy of Dr. Carlos Fava.

 

TAVR: The Need for a Pacemaker

After a transcatheter aortic valve replacement (TAVR), the incidence of permanent pacemaker (PPM) implantation ranges from 6% to 30% in different studies, depending on the valve type used. This is due to trauma, ischemia, haemorrhage, and atrioventricular node and infranodal tissue oedema, provoking ventricular dyssynchrony similar to that caused by complete left bundle branch block. The evolution of patients requiring permanent pacemaker after TAVR has not been fully studied.

 

This study included 9785 patients from 229 hospitals; 651 (6.65%) of these subjects received a permanent pacemaker.

 

Patients receiving a permanent pacemaker were more frequently men with a higher STS predicted risk of mortality score (7.3% vs. 6.7%; p = 0.004), who received aortic valvuloplasty less often and presented more conduction defects in the baseline echocardiogram.

 

During the procedure, patients requiring a permanent pacemaker received larger valves, with higher oversizing. Mean time between valve replacement and permanent pacemaker implantation was three days.

 

Self-expanding valves (CoreValve) required the implantation of permanent pacemakers more frequently than balloon-expandable valves (E. Sapiens). Extreme-risk or inoperable patients required a permanent pacemaker more frequently than high-risk patients. Hospital stays were longer for patients requiring a PPM.

 

At a year, the need for a permanent pacemaker was associated with an increase in mortality (24.1% vs. 19.6%; hazard ratio [HR]: 1.31; 95% confidence interval [CI]: 1.09 to 1.58) and an increase in a composite of mortality and heart failure (37.3% vs. 28.5%; HR: 1.33; 95% CI: 1.13 to 1.56).

 

The following were predictors of the need for permanent pacemaker implantation after TAVR at 30 days:

  • age;
  • prior conduction defect;
  • aortic valve area ≤0.75 cm2;
  • use of self-expanding valves.

 

Conclusion

The need for a pacemaker is a common complication following TAVR, and it is associated with higher mortality and hospitalization due to heart failure at one year.

 

Editorial

Prior studies argued that permanent pacemaker implantation did not affect outcomes. This study, however, proves the opposite: it is associated to a hard event, mortality, and a higher need for hospitalization due to heart failure. This also increases healthcare costs.

 

The upcoming challenge lies in the development of devices that lower the need for a permanent pacemaker while maintaining or improving current performance.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry.

Reference: Opeyemi O. FadaHunsi, et al. J Am Coll Cardiol Intv 2016;9:2189-99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...